Adverse reaction profile of sulfasalazine and its persistence in chronic therapy of rheumatoid arthritis and spondyloarthritis: A multicentric observational study.

IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY International journal of clinical pharmacology and therapeutics Pub Date : 2022-06-17 DOI:10.5414/CP204120
Mamatha Jayachandran, V. Koshy, Rosme David, Vanditha Santhakumari, D. Padmanabhan, S. Surendran, ArunKr. Tiwari, C. Mithun, S. Singh, Saroj Kumar Suman, P. Yadav, A. Singhal, A. Nair, V. Marwaha, P. Palatty
{"title":"Adverse reaction profile of sulfasalazine and its persistence in chronic therapy of rheumatoid arthritis and spondyloarthritis: A multicentric observational study.","authors":"Mamatha Jayachandran, V. Koshy, Rosme David, Vanditha Santhakumari, D. Padmanabhan, S. Surendran, ArunKr. Tiwari, C. Mithun, S. Singh, Saroj Kumar Suman, P. Yadav, A. Singhal, A. Nair, V. Marwaha, P. Palatty","doi":"10.5414/CP204120","DOIUrl":null,"url":null,"abstract":"OBJECTIVES\nSulfasalazine has been widely used in treatment of rheumatoid arthritis and spondyloarthritis. This study aims to assess persistence with sulfasalazine and also frequency and severity of adverse drug reactions (ADRs) encountered with this very well-established disease-modifying anti-rheumatoid drug.\n\n\nMATERIALS AND METHODS\nThis retrospective study was done in 1,114 patients from medicine and rheumatology outpatient departments of six centers across India. The inclusion criteria was patients taking sulfasalazine. Patients receiving sulfasalazine for rheumatoid arthritis or spondyloarthritis were selected and details on drugs used, duration of taking sulfasalazine, ADRs to sulfasalazine and whether sulfasalazine had to be stopped due to ADRs were analyzed.\n\n\nRESULTS\nOf the total of patients included in the study, 10.1% had ADRs with sulfasalazine, and stopped the drug. Gastritis, deranged liver enzymes, hepatitis, skin rashes were the most commonly encountered ADRs. Of the total number of patients recruited for the study, 11% were lost to follow-up, as most of the centers were army hospitals and the officers and staff were posted to other places. Sulfasalazine was taken for less than 1 month by 3.8% patients while 12.5% had taken the drug for less than 6 months. Of the study patients, 28.6% had taken the drug for 24 - 60 months and 4.6% (51 patients) had taken it for more than 5 years. It was found that ADRs were most commonly encountered within the first year of using the drug, and persistence was seen in patients on long-term therapy.\n\n\nCONCLUSION\nSulfasalazine is a safe option in chronic therapy of rheumatoid arthritis and spondyloarthritis. Although frequency of ADRs with patients taking sulfasalazine is minimal, it did necessitate the stoppage of drug. If not well tolerated, sulfasalazine would not have been continued for more than 12 months as evidenced from this study.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

Abstract

OBJECTIVES Sulfasalazine has been widely used in treatment of rheumatoid arthritis and spondyloarthritis. This study aims to assess persistence with sulfasalazine and also frequency and severity of adverse drug reactions (ADRs) encountered with this very well-established disease-modifying anti-rheumatoid drug. MATERIALS AND METHODS This retrospective study was done in 1,114 patients from medicine and rheumatology outpatient departments of six centers across India. The inclusion criteria was patients taking sulfasalazine. Patients receiving sulfasalazine for rheumatoid arthritis or spondyloarthritis were selected and details on drugs used, duration of taking sulfasalazine, ADRs to sulfasalazine and whether sulfasalazine had to be stopped due to ADRs were analyzed. RESULTS Of the total of patients included in the study, 10.1% had ADRs with sulfasalazine, and stopped the drug. Gastritis, deranged liver enzymes, hepatitis, skin rashes were the most commonly encountered ADRs. Of the total number of patients recruited for the study, 11% were lost to follow-up, as most of the centers were army hospitals and the officers and staff were posted to other places. Sulfasalazine was taken for less than 1 month by 3.8% patients while 12.5% had taken the drug for less than 6 months. Of the study patients, 28.6% had taken the drug for 24 - 60 months and 4.6% (51 patients) had taken it for more than 5 years. It was found that ADRs were most commonly encountered within the first year of using the drug, and persistence was seen in patients on long-term therapy. CONCLUSION Sulfasalazine is a safe option in chronic therapy of rheumatoid arthritis and spondyloarthritis. Although frequency of ADRs with patients taking sulfasalazine is minimal, it did necessitate the stoppage of drug. If not well tolerated, sulfasalazine would not have been continued for more than 12 months as evidenced from this study.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
磺胺吡啶在类风湿性关节炎和脊椎关节炎慢性治疗中的不良反应及其持续性:一项多中心观察性研究。
目的硫柳嗪已广泛应用于类风湿性关节炎和脊椎关节炎的治疗。本研究旨在评估柳氮磺胺吡啶的持久性,以及这种公认的治疗疾病的抗类风湿药物出现的不良反应(ADR)的频率和严重程度。材料和方法这项回顾性研究对来自印度六个中心的1114名内科和风湿病门诊患者进行。纳入标准为服用柳氮磺胺吡啶的患者。选择接受柳氮磺胺吡啶治疗类风湿性关节炎或脊椎关节炎的患者,分析所用药物、服用柳氮磺胺嘧啶的持续时间、柳氮磺胺的不良反应以及是否因不良反应而必须停用柳氮磺胺。结果在纳入研究的所有患者中,10.1%的患者出现柳氮磺胺吡啶的不良反应,并停药。胃炎、肝酶紊乱、肝炎、皮疹是最常见的不良反应。在为这项研究招募的患者总数中,11%的患者失去了随访,因为大多数中心都是军队医院,军官和工作人员被派往其他地方。3.8%的患者服用柳氮磺吡啶不到1个月,12.5%的患者服用该药物不到6个月。在研究患者中,28.6%的患者服用该药物24-60个月,4.6%(51名患者)服用该药物超过5年。研究发现,不良反应最常见于使用该药物的第一年,长期治疗的患者会出现持续性不良反应。结论柳氮磺吡啶是治疗类风湿性关节炎和脊椎关节炎的安全选择。尽管服用柳氮磺胺吡啶的患者出现不良反应的频率很低,但确实需要停药。如果不能很好地耐受,柳氮磺胺吡啶就不会持续超过12个月,这项研究证明了这一点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
12.50%
发文量
116
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.
期刊最新文献
Identification of factors associated with vancomycin-induced acute kidney injury: A retrospective analysis using the Common Data Model. Retrospective evaluation of medical information for predicting tazobactam/piperacillin-induced liver injury. A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. Positive effects of magnesium supplementation in metabolic syndrome. Corrigendum for the article Int J Clin Pharmacol Ther 2024; 11: 525-533.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1